Auditory MMN EEG in TRD in Response to Ketamine

Launched by UNITY HEALTH TORONTO · Jul 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how well ketamine can help people with treatment-resistant depression (TRD), which is a type of depression that doesn’t improve with standard treatments. The researchers are trying to create a model that can predict how patients will respond to ketamine. They are currently looking for participants aged 18 to 65 who are experiencing a major depressive episode and have not found relief after trying at least two different antidepressant medications. To be eligible, participants must also be able to understand the study and stay on their current medications without changes.

If you join this trial, you can expect to receive ketamine treatment as part of your care. The study aims to gather information that could help improve future treatments for people with TRD. It's important to note that individuals with a history of bipolar disorder, psychosis, or substance use in the past year, as well as those with certain medical conditions, will not be able to participate. This is a great opportunity to contribute to research that may help others struggling with similar challenges in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.18 to 65 years of age 2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for MDD and in a Major Depressive Episode and ≥10 on the Montgomery-Asberg Depression Rating Scale (MADRS).
• • 3. Competent to consent-based on their ability to provide a spontaneous narrative description of the key elements of the study.
• • 4. Failure of at least two trials of antidepressant therapy during the current episode (treatment-resistant depression) and receiving ketamine treatment clinically as administered by their clinician 5. Staying on stable dosages of any concomitant psychotropic medications.
• Exclusion Criteria:
• • 1. History of bipolar disorder or psychosis
• • 2. Current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder)
• • 3. Concomitant major and unstable medical or neurologic illness or a history of seizures.
• • 4. Non-English-speaking individuals.